Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
28,000
Employees28,000
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
28,000
Employees28,000

AMGN Key Statistics

Market cap
181.71B
Market cap181.71B
Price-Earnings ratio
26.09
Price-Earnings ratio26.09
Dividend yield
2.78%
Dividend yield2.78%
Average volume
3.07M
Average volume3.07M
High today
$342.84
High today$342.84
Low today
$334.74
Low today$334.74
Open price
$335.75
Open price$335.75
Volume
4.09M
Volume4.09M
52 Week high
$345.84
52 Week high$345.84
52 Week low
$253.30
52 Week low$253.30

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $337.54. The company's market cap stands at 181.71B, with a P/E ratio of 26.09 and a dividend yield of 2.8%.

On 2025-11-22, Amgen(AMGN) stock moved within a range of $334.74 to $342.84. With shares now at $337.54, the stock is trading +0.8% above its intraday low and -1.5% below the session's peak.

Trading activity shows a volume of 4.09M, compared to an average daily volume of 3.07M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $345.84 and a low of $253.30.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $345.84 and a low of $253.30.

AMGN News

TipRanks 2h
Teva, Amgen, Rithm, Fastly, Medtronic: Major Stock Moves!

Insiders have been trading these 5 stocks: ((TEVA)), ((AMGN)), ((RITM)), ((FSLY)) and ((MDT)). Here is a breakdown of their recent trades and their value. TipR...

Investor's Business Daily 18h
Amgen Shines As Medical Sector Benefits From Sector Rotation

Blue Chips, Value-Oriented Firms Reign Over Market Gains; Is Leadership's Complexion Changing? 11/11/2025 Amgen's riveting 14% gain over five sessions stands i...

Amgen Shines As Medical Sector Benefits From Sector Rotation
Nasdaq 2d
Dow Movers: AMGN, WMT

In early trading on Thursday, shares of Walmart topped the list of the day's best performing Dow Jones Industrial Average components, trading up 4.4%. Year to d...

Dow Movers: AMGN, WMT

Analyst ratings

47%

of 34 ratings
Buy
44.1%
Hold
47.1%
Sell
8.8%

More AMGN News

Simply Wall St 2d
Don't Ignore The Insider Selling In Amgen

We wouldn't blame Amgen Inc. ( ) shareholders if they were a little worried about the fact that Murdo Gordon, the Executive Vice President of Global Commercial...

Don't Ignore The Insider Selling In Amgen
Nasdaq 3d
Amgen's IMDELLTRA Gets Full FDA Approval For Extensive Stage Small Cell Lung Cancer

(RTTNews) - Amgen (AMGN) announced that the U.S. Food and Drug Administration has granted full approval to IMDELLTRA (tarlatamab-dlle) for the treatment of adul...

Amgen's IMDELLTRA Gets Full FDA Approval For Extensive Stage Small Cell Lung Cancer
TipRanks 3d
Amgen says FDA grants full approval to IMDELLTRA

Amgen (AMGN) announced that the U.S. FDA has granted full approval to IMDELLTRA for the treatment of adult patients with extensive stage small cell lung cancer...

Nasdaq 3d
Ex-Dividend Reminder: NextEra Energy, Amgen and CRH

Looking at the universe of stocks we cover at Dividend Channel, on 11/21/25, NextEra Energy Inc (Symbol: NEE), Amgen Inc (Symbol: AMGN), and CRH plc (Symbol: CR...

Ex-Dividend Reminder: NextEra Energy, Amgen and CRH
Simply Wall St 3d
Amgen: Reviewing Valuation After Recent Share Price Gains

Amgen (AMGN) shares have delivered a 16% return over the past three months, catching the attention of investors interested in steady growth. The company's recen...

Amgen: Reviewing Valuation After Recent Share Price Gains
Simply Wall St 5d
Amgen Is Up 5.6% After Repatha Phase 3 Trial Shows Cardiovascular Benefits – Has The Bull Case Changed?

Earlier this month, Amgen announced detailed results from its Phase 3 VESALIUS-CV clinical trial, showing that Repatha® (evolocumab) achieved statistically sign...

Amgen Is Up 5.6% After Repatha Phase 3 Trial Shows Cardiovascular Benefits – Has The Bull Case Changed?
Nasdaq 5d
Dow Movers: NKE, AMGN

In early trading on Monday, shares of Amgen topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.2%. Year to date,...

Dow Movers: NKE, AMGN

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.